Nanoparticles as delivery vehicles of active ingredients and methods for the production thereof

Patent metadata

Field	Value
Publication number	US-11344499-B2
Application number	US-201816622402-A
Country	US
Kind code	B2
Filing date	Jun 13, 2018
Priority date	Jun 16, 2017
Publication date	May 31, 2022
Grant date	May 31, 2022

Abstract

A nanoparticle comprising a keratin polypeptide and at least one lipophilic active ingredient, wherein the at least one lipophilic active ingredient is non-covalently bound to the keratin polypeptide and can be e.g. a therapeutic or diagnostic agent, a nutraceutical, a cosmetic ingredients, a dye or a cosmeceutical, the keratin polypeptide being water-soluble; optionally, the nanoparticle further comprises at least one hydrophilic active ingredient non-covalently bound to the keratin polypeptide, which can be e.g. a therapeutic or diagnostic agent, a nutraceutical, a cosmetic ingredients, a dye or a cosmeceutical.

First claim

The invention claimed is:

1. A nanoparticle comprising a keratin polypeptide and at least one lipophilic active ingredient, wherein
said at least one lipophilic active ingredient is non-covalently bound to said keratin polypeptide,
said keratin polypeptide is water-soluble, and
said keratin polypeptide is a wild-type keratin polypeptide having a molecular weight higher than 14 kDa or a wild-type keratin polypeptide, having a molecular weight higher than 14 kDa which has been modified by chemical functionalization of the N-terminus with organic compounds and/or chemical functionalization of amino acid side chains therein with hydroxyl, amino and thiol groups.

2. The nanoparticle according to claim 1 , wherein said at least one lipophilic active ingredient is selected from the group consisting of therapeutic agents, diagnostic agents, nutraceuticals, cosmetic ingredients, dyes and cosmeceuticals.

3. The nanoparticle according to claim 1 , wherein said nanoparticle further comprises at least one hydrophilic active ingredient non-covalently bound to said keratin polypeptide.

4. The nanoparticle according to claim 3 , wherein said at least one hydrophilic active ingredient is selected from the group consisting of therapeutic agents, diagnostic agents, nutraceuticals, cosmetic ingredients, dyes and cosmeceuticals.

5. The nanoparticle according to claim 2 , wherein said at least one lipophilic active ingredient is a therapeutic agent selected from the group consisting of anticancer drugs, anti-inflammatory agents, antimicrobial agents, analgesics, hormones, anaesthetic agents, antianginals; anti-arrhythmic drugs; antibacterial and antiprotozoal agents; anti-coagulants; antidepressants; anti-diabetic drugs; anti-epileptic drugs; antifungal agents; antihistamines; anti-hypertensive drugs; anti-muscarinic agents; antineoplastic agents; anti-migraine drugs; anti-parasitic agents; anti-Parkinsonian drugs; antipsychotic, hypnotic and sedating agents; anti-stroke agents; anti-thrombotic agents; antitussives; antivirals; beta-adrenoceptor blocking agents; calcium channel blockers; cardiac inotropic agents; contraceptive agents; corticosteroids; dermatological agents; diuretics; gastro-intestinal agents; haemostatics; local anaesthetics; opioid analgesics; parasympathomimetics; peptides; steroids; stimulating agents; and vasodilators.

6. The nanoparticle according to claim 5 , wherein said therapeutic agent is an anticancer drug, optionally selected from the group consisting of methotrexate, cisplatin; topotecan; 5-fluorouracil, thiotopotecan, thiocamptothecin, camptothecin, paclitaxel, docetaxel, doxorubicin, bicalutamide, MDV3100 enzalutamide, 9-hydroxyl stearic acid, curcumin, irinotecan hydrochloride, vinblastine, histone methyltransferases inhibitors, carboplatin, methylene blue, Azure A (N,N-dimethylthionine chloride), porphyrins and chlorins.

7. The nanoparticle according to claim 4 , wherein said at least one hydrophilic active ingredient is a therapeutic agent selected from the group consisting of anticancer drugs, anti-inflammatory agents, antimicrobial agents, analgesics, hormones, anaesthetic agents, antianginals; anti-arrhythmic drugs; antibacterial and antiprotozoal agents; anti-coagulants; antidepressants; anti-diabetic drugs; anti-epileptic drugs; antifungal agents; antihistamines; anti-hypertensive drugs; anti-muscarinic agents; antineoplastic agents; anti-migraine drugs; anti-parasitic agents; anti-Parkinsonian drugs; antipsychotic, hypnotic and sedating agents; anti-stroke agents; anti-thrombotic agents; antitussives; antivirals; beta-adrenoceptor blocking agents; calcium channel blockers; cardiac inotropic agents; contraceptive agents; corticosteroids; dermatological agents; diuretics; gastro-intestinal agents; haemostatics; local anaesthetics; opioid analgesics; parasympathomimetics; peptides; steroids; stimulating agents; and vasodilators.

8. The nanoparticle according to claim 1 , wherein said nanoparticle contains an amount of said at least one lipophilic active ingredient ranging from 5% to about 45% by weight of the weight of said nanoparticle.

9. The nanoparticle according to claim 1 , wherein said nanoparticle has a diameter between 1 nm to 400 nm, or between 100-200 nm.

10. A pharmaceutical composition comprising the nanoparticles according to claim 5 , and a pharmaceutically acceptable carrier.

11. A pharmaceutical formulation comprising the composition according to claim 10 for parenteral or oral administration.

12. A pharmaceutical composition comprising the nanoparticles according to claim 6 , and a pharmaceutically acceptable carrier.

13. A pharmaceutical formulation comprising the composition according to claim 12 for parenteral or oral administration.

14. A cosmetic formulation for topical application, comprising the nanoparticles according to claim 4 and a cosmetically acceptable vehicle.

15. A cosmetic formulation for topical application, comprising the nanoparticles according to claim 2 , and a cosmetically acceptable vehicle.

16. A functional food comprising the nanoparticles according to claim 1 , wherein the functional food is selected from the group consisting of cereal bars, yogurt dairy products, bakery products, fruit juices and drinks.

17. A method for producing the nanoparticle according to claim 1 , comprising:
a) dissolving the keratin polypeptide in water or in a buffered aqueous solution at concentrations ranging from 1 to 5 mg/mL at room temperature, thereby obtaining a solution;
b) filtering said solution; and
c) adding said at least one lipophilic active ingredient previously dissolved in an organic solvent to said solution obtained in step b) under stirring.

18. A method of treating a patient suffering from a neoplastic disease, which comprises administering to the patient a therapeutically effective amount of the nanoparticle according to claim 6 , wherein said neoplastic diseases are selected from the group consisting of breast cancer, ovarian cancer, prostate cancer, lung cancer, colon cancer, colorectal cancer, pancreatic cancer, gastrointestinal stromal tumor, adrenal cancer, skin melanoma, non-skin melanoma, mouth cancer, eye tumor, nasal cavity and paranasal sinus cancer, penile cancer, bronchial carcinoma, heart cancer, uterine body cancer, cervical cancer, esophageal cancer, liver cancer, metastatic pancreatic cancer, lymphomas, Hodgkin lymphoma, non-Hodgkin lymphoma, cutaneous lymphoma, pediatric lymphomas, laryngeal cancer, pharyngeal cancer, malignant mesothelioma, leukemias, hairy cell leukaemia, chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia, acute myeloid leukaemia, chronic myeloid leukaemia, pediatric leukemia, multiple myeloma, sarcomas, gliomas, renal cancer, testicular cancer, thyroid cancer, soft tissue sarcoma, bone sarcoma, Ewing sarcoma, Kaposi sarcoma, extraskeletal Ewing sarcoma, chondrosarcoma, osteosarcoma, metastatic bone cancer, choriocarcinoma, pineal gland cancer, salivary gland tumors, hypophysis cancer, primitive neuroectodermal tumour, multiple endocrine neoplasia type 1 (MEN1), Multiple Endocrine Neoplasia Type 2 (MEN2), bladder cancer, tumors of the pelvic organs, ureteral cancer, oral cavity cancer, anal cancer, vulvar cancer, vaginal cancer, spleen cancer, brain tumors, embryonal tumors, gall-bladder cancer, bile duct cancer, cancer cachexia, neuroblastoma cancer, pediatric neuroblastoma cancer, neuroendocrine cancer, pediatric tumors and Myeloproliferative neoplasms.

19. A method comprising administering the nanoparticle according to claim 5 by topical ap

Assignees

• Consiglio Nazionale Ricerche

Inventors

• Aluigi Annalisa
• Varchi Greta
• Sotgiu Giovanna
• Guerrini Andrea
• Ballestri Marco

Classifications

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61K31/20

  having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids · CPC title

• A61K2800/413

  Nanosized, i.e. having sizes below 100 nm · CPC title

• A61K8/4973

  with oxygen as the only hetero atom · CPC title